realtim
quantit
revers
transcriptas
polymeras
chain
reaction
rrtpcr
wide
use
detect
viral
pathogen
variou
human
specimen
applic
intern
control
valid
entir
process
assay
necessari
prevent
falseneg
result
caus
unexpect
inhibit
ineffici
extract
present
studi
describ
strategi
produc
stabl
intern
control
rrtpcr
packag
foreign
rna
influenza
virion
use
plasmidbas
revers
genet
technolog
envelop
structur
influenza
viru
effect
protect
rna
segment
rnase
digest
provid
advantag
routin
use
intern
control
util
approach
success
gener
recombin
influenza
viru
contain
untransl
region
utr
hepat
c
viru
hcv
rna
genom
inactiv
purif
particl
demonstr
rnase
resist
stabl
least
day
human
plasma
degrad
even
frozen
thaw
multipl
time
result
reproduc
coba
taqman
hcv
test
day
moreov
chimer
influenza
viru
particl
could
easili
produc
embryon
egg
noninfecti
inactiv
treatment
addit
strategi
could
also
adapt
realtim
clinic
applic
rna
target
provid
univers
approach
broad
clinic
applic
rrtpcr
assay
realtim
quantit
revers
transcriptas
polymeras
chain
reaction
rrtpcr
assay
wide
use
diagnost
tool
detect
quantif
viral
rna
clinic
sampl
espi
et
al
howev
inher
problem
frequent
encount
falseneg
pcr
result
caus
mainli
degrad
target
rna
presenc
pcr
inhibitor
therefor
intern
control
incorpor
assay
ensur
reliabl
pcr
result
trueneg
result
distinguish
falseneg
result
due
human
error
inhibit
hoorfar
et
al
ideal
intern
control
close
mimic
natur
viru
order
monitor
stage
rrtpcr
includ
nucleic
acid
extract
rna
revers
transcript
amplif
niester
paslosk
et
al
addit
intern
control
easi
prepar
stabl
safe
routin
use
current
mani
diagnost
assay
viral
rna
detect
quantifi
use
nake
rna
control
chang
et
al
scholt
et
al
wernik
et
al
howev
nake
rna
unstabl
suscept
degrad
rnase
dreier
et
al
felder
wolfel
furthermor
use
nake
rna
control
lysi
process
monitor
rna
extract
therefor
partial
qualiti
assur
achiev
thu
develop
improv
intern
control
viral
nucleic
acid
amplif
test
utmost
import
armor
rna
noninfecti
synthet
pseudovir
particl
produc
packag
exogen
target
rna
sequenc
coat
protein
paslosk
et
al
date
appropri
strategi
rna
control
prepar
serv
surrog
primari
target
viru
owe
safeti
rnase
resist
stabil
prolong
incub
plasma
huang
et
al
technolog
success
adapt
prepar
intern
control
variou
rrtpcr
assay
human
immunodefici
viru
hiv
hepat
c
viru
hcv
enteroviru
influenza
virus
okello
et
al
paslosk
et
al
song
et
al
sun
et
al
walkerpeach
et
al
howev
commerci
avail
armor
rna
prepar
expens
owe
patent
protect
us
patent
number
http
asuragen
com
greatli
limit
widespread
applic
routin
clinic
laboratori
influenza
viru
belong
famili
orthomyxovirida
envelop
negativesens
rna
viru
segment
singlestrand
genom
revers
genet
technolog
use
gener
chimer
influenza
virus
contain
foreign
rna
fragment
base
modif
influenza
viru
intern
gene
de
baet
et
al
reec
et
al
wu
et
al
previou
studi
shown
influenza
viru
carri
report
gene
gfp
replic
normal
stabli
express
report
gene
infect
cell
make
virus
feasibl
extens
propag
li
et
al
manicassami
et
al
furthermor
virion
morpholog
chimer
virus
indistinguish
wildtyp
virus
observ
electron
microscopi
indic
chimer
virus
may
rnase
resist
lipid
envelop
protect
maloney
et
al
wu
et
al
therefor
conclud
chimer
influenza
viru
carri
target
rna
fragment
could
potenti
use
intern
control
rrtpcr
present
studi
base
manipul
influenza
viru
develop
novel
artifici
rna
control
hcv
rrtpcr
assay
use
revers
genet
technolog
accomplish
insert
untransl
region
utr
hcv
nonstructur
protein
ns
segment
influenza
viru
inactiv
purifi
chimer
virus
ad
appropri
clinic
sampl
matric
hcv
also
demonstr
influenza
viru
good
potenti
use
vector
stabl
lowcost
intern
control
prepar
cell
atcc
purchas
atcc
maintain
dulbecco
modifi
eagl
medium
dmem
contain
fetal
bovin
serum
fb
plasmid
kindli
provid
e
hoffmann
r
g
webster
hoffmann
et
al
revers
complement
sequenc
highli
conserv
hcv
utr
nt
genbank
access
insert
influenza
apuerto
ns
gene
genbank
access
use
overlap
extens
pcr
first
round
pcr
three
separ
fragment
amplifi
follow
includ
genom
noncod
region
lack
stop
codon
nep
includ
genom
noncod
region
amplifi
phwn
plasmid
construct
laboratori
use
primer
pair
hcv
nepolf
hcv
nsr
hcv
utr
peptidecod
sequenc
amplifi
plasmid
construct
laboratori
use
primer
hcvolf
hcvolr
nep
cleanup
hcv
plu
nep
fragment
construct
subsequ
round
pcr
use
primer
hcvolf
nsr
pcr
product
gel
purifi
final
round
pcr
fuse
n
termin
hcvnep
via
short
gsg
linker
use
primer
nsf
nsr
introduc
silent
mutat
splice
acceptor
site
nucleotid
replac
use
primer
primer
sequenc
use
studi
shown
tabl
engin
nshcv
segment
clone
bsmbi
site
vector
gener
chimer
plasmid
phwnshcv
construct
sequenc
across
entir
ns
gene
confirm
insert
chimer
plasmid
carri
seven
gene
segment
viru
pa
ha
np
na
alreadi
construct
previou
studi
wang
et
al
method
gener
chimer
influenza
virus
perform
describ
previous
hoffmann
et
al
wang
et
al
briefli
cell
transfect
eight
express
plasmid
viral
gene
genbank
access
genbank
access
pa
genbank
access
ha
genbank
access
np
genbank
access
na
genbank
access
genbank
access
nshcv
use
lipofectamin
plasmid
invitrogenlif
technolog
usa
fortyeight
hour
transfect
supernat
cell
collect
subsequ
inocul
specif
pathogenfre
chicken
embryo
viru
propag
h
postinocul
allanto
fluid
harvest
centrifug
min
remov
cell
debri
harvest
allanto
fluid
subject
hemagglutin
ha
assay
determin
presenc
virus
explor
stabil
chimer
virus
subcultur
chicken
embryo
eight
passag
rna
extract
serial
passag
rtpcr
amplif
partial
nshcv
gene
fragment
use
primer
hcvolf
nsr
inactiv
viru
stock
mix
formalin
day
inactiv
virus
confirm
absenc
detect
ha
activ
three
passag
treat
materi
embryon
egg
inactiv
virus
purifi
sucros
gradient
centrifug
h
purifi
virus
suspend
phosphatebuff
salin
store
rtpcr
sequenc
use
confirm
ident
nshcv
gene
prepar
viru
stock
rna
extract
purifi
particl
use
trizol
reagent
accord
manufactur
instruct
life
technolog
usa
briefli
purifi
virus
mix
trizol
reagent
incub
rnawa
separ
aqueou
phase
addit
chloroform
rna
precipit
isopropanol
wash
ethanol
resuspend
rnasefre
water
rna
sampl
kept
ice
use
confirm
gener
viru
contain
chimer
nshcv
segment
rna
electrophoresi
perform
briefli
extract
rna
run
polyacrylamid
gel
contain
urea
v
h
stain
silver
stain
kit
biorad
hercul
ca
usa
revers
transcript
rt
reaction
perform
reaction
mixtur
contain
purifi
rna
unit
primer
rt
buffer
mm
deoxynucleosid
triphosph
rnase
inhibitor
amv
revers
transcriptas
promega
madison
wi
usa
rt
reaction
perform
use
geneamp
pcr
system
appli
biosystem
foster
citi
ca
usa
min
follow
min
revers
transcriptas
inactiv
assess
incorpor
chimer
nshcv
gene
segment
rescu
virion
pcr
perform
final
reaction
mixtur
contain
cdna
obtain
rt
reaction
primer
amplif
differ
gene
ns
hcv
np
gene
pcr
buffer
mm
deoxynucleosid
triphosph
high
fidel
pcr
enzym
mix
thermo
fisher
scientif
rockford
il
usa
initi
denatur
min
amplif
cycl
min
min
min
perform
follow
final
extens
min
pcr
product
analyz
electrophoresi
agaros
gel
visual
ethidium
bromid
stain
pcr
product
purifi
subclon
vector
takara
dalian
china
verifi
sequenc
examin
whether
purifi
particl
nucleas
resist
particl
rna
isol
particl
incub
rnase
qiagen
hilden
germani
h
treatment
sampl
test
use
commerci
hcv
rna
pcr
bsmb
restrict
site
indic
underscor
silent
mutat
indic
boldfac
type
fluoresc
quantit
diagnost
kit
shanghai
kehua
bioengin
shanghai
china
stabil
particl
examin
human
plasma
seroneg
hcv
rna
antihcv
hcv
rna
pcr
kit
sansur
biotech
hunan
china
use
sampl
quantif
sampl
contain
approxim
iuml
quantifi
particl
prepar
normal
human
edtapreserv
plasma
stabil
studi
singl
batch
particl
separ
aliquot
individu
time
point
sampl
volum
use
real
time
pcr
assay
sampl
incub
room
temperatur
set
period
time
sampl
quantifi
duplic
time
point
data
analyz
use
softwar
appli
biosystem
foster
citi
ca
usa
particl
store
thaw
room
temperatur
five
time
quantifi
duplic
order
investig
whether
chimer
serv
posit
control
clinic
diagnosi
roch
coba
ampliprepcoba
taqman
system
capctm
use
system
wide
use
realtim
pcr
assay
hcv
rna
quantif
capctm
combin
autom
extract
hcv
rna
coba
ampliprep
instrument
realtim
pcr
coba
taqman
analyz
thu
greatli
reduc
time
need
sampl
prepar
amplif
detect
previou
studi
shown
capctm
sensit
specif
precis
reproduc
broad
dynam
rang
quantif
bossler
et
al
sarrazin
et
al
first
quantifi
dilut
normal
human
plasma
final
hcv
rna
concentr
approxim
iuml
total
volum
ml
aliquot
sampl
store
use
sampl
assay
parallel
coba
taqman
hcv
test
posit
control
regular
clinic
run
determin
hcv
viral
load
control
posit
control
coba
taqman
hcv
test
kit
assay
week
approxim
month
linear
analysi
rrtpcr
assay
hcv
particl
serial
dilut
normal
human
plasma
obtain
concentr
iuml
three
replic
concentr
test
assay
run
use
hcv
rna
pcr
kit
sansur
biotech
hunan
china
result
quantif
valu
averag
assay
data
natur
log
transform
prior
analysi
chang
hcv
rna
level
time
evalu
linear
regress
describ
previous
jose
et
al
krajden
et
al
p
valu
consid
statist
signific
gener
influenza
viru
contain
hcv
utr
segment
ns
gene
viru
modifi
express
nep
monocistron
autoproteolyt
cleavag
site
cleavag
site
allow
nep
translat
independ
fusion
protein
splice
acceptor
site
remov
prevent
splice
ns
mrna
addit
origin
translat
stop
codon
tgawa
delet
sitedirect
mutagenesi
hcv
gene
could
fuse
protein
product
result
cdna
insert
bidirect
express
plasmid
obtain
phwnshcv
construct
fig
recombin
influenza
viru
name
success
rescu
cotransfect
plasmid
contain
seven
influenza
gene
cell
describ
bmateri
method
fig
success
incorpor
nshcv
virion
examin
silver
stain
expect
absenc
ns
segment
within
viru
observ
viru
chimer
nshcv
segment
along
np
segment
migrat
nearli
posit
fig
specif
nshcv
chimer
dna
could
readili
detect
passag
chimer
virus
demonstr
viru
genet
stabl
fig
ensur
safeti
chimer
viru
use
posit
control
virus
treat
formalin
ha
activ
examin
result
show
ha
activ
observ
three
passag
viru
embryon
egg
data
shown
indic
treatment
result
complet
loss
viral
infect
inactiv
purifi
sucros
gradient
centrifug
total
rnawa
isol
rtpcr
perform
follow
sequenc
size
gener
cdna
confirm
fulllength
chimer
nshcv
gene
packag
chimer
viru
fig
dna
sequenc
reveal
neither
loss
gene
segment
chang
nucleotid
acid
sequenc
inactiv
formalin
data
shown
result
indic
chimer
influenza
virus
success
obtain
also
demonstr
formalin
treatment
destroy
structur
viru
durabl
chimer
particl
test
subject
rnase
treatment
result
show
particl
complet
resist
rnase
treatment
nake
rna
degrad
rapidli
rnase
digest
fig
suggest
purifi
particl
contain
intact
virion
could
protect
encapsul
rna
rnase
degrad
stabil
purifi
prepar
examin
human
plasma
two
hundr
microlit
dilut
iuml
incub
fig
gener
recombin
influenza
viru
schemat
represent
ns
segment
wildtyp
viru
top
viru
bottom
prevent
mrna
splice
silent
mutat
introduc
splice
acceptor
site
nucleotid
hcv
utr
sequenc
dark
insert
bautocleavep
tv
peptidecod
sequenc
via
short
gsg
linker
result
fragment
fuse
nep
open
read
frame
gray
b
eightplasmid
viru
rescu
system
seven
plasmid
phwpa
phwha
phwnp
phwna
phwm
one
nsbase
construct
phwnshcv
use
gener
viru
revers
genet
c
rna
electrophoresi
rna
isol
purifi
virus
run
acrylamid
gel
visual
silver
stain
posit
polymeras
ps
ha
np
na
ns
nshcv
segment
indic
viral
genom
stabil
analysi
chimer
influenza
virus
consecut
inocul
chicken
embryo
eight
passag
ns
hcvnep
gene
detect
use
rtpcr
phwnshcv
plasmid
use
posit
control
pc
fig
rtpcr
detect
ns
hcv
np
gene
purifi
influenza
virus
ns
upper
hcv
middl
np
lower
gene
purifi
detect
use
rtpcr
day
day
day
follow
rna
extract
hcv
realtim
pcr
analysi
shown
fig
signific
differ
stabil
high
low
concentr
sampl
store
temperatur
p
loss
signal
observ
sampl
maintain
indic
temperatur
could
ensur
stabil
least
month
plasma
mean
low
concentr
sampl
iu
ml
log
rang
iuml
coeffici
variat
mean
high
concentr
sampl
iuml
log
rang
iuml
coeffici
variat
howev
sampl
plasma
stabl
day
day
suggest
sampl
kept
temperatur
complet
stabl
long
time
p
moreov
sampl
purifi
human
plasma
underw
longterm
storag
month
show
declin
viral
load
compar
origin
concentr
data
shown
addit
prepar
high
low
concentr
human
plasma
stabl
five
freezethaw
cycl
data
shown
assess
perform
particl
posit
control
clinic
viral
load
test
sampl
assay
comparison
posit
control
coba
taqman
hcv
test
kit
noninfecti
armor
fig
resist
purifi
rnase
equal
amount
isol
rna
incub
rnase
h
digest
sampl
test
realtim
pcr
fig
stabil
evalu
particl
ad
human
plasma
final
concentr
iuml
sampl
incub
room
temperatur
set
period
time
sampl
qualifi
duplic
time
point
use
hcv
rna
pcr
fluoresc
quantit
diagnost
kit
detect
result
averag
chang
hcv
rna
level
sampl
evalu
linear
regress
analysi
rna
construct
contain
hcv
gene
fragment
colucci
et
al
control
mean
iuml
log
rang
iu
ml
coeffici
variat
posit
control
provid
within
commerci
kit
mean
iu
ml
log
rang
iuml
coeffici
variat
result
show
coeffici
variat
control
commerci
kit
control
compar
demonstr
control
perform
reliabl
control
provid
commerci
kit
fig
perform
calibr
realtim
pcr
assay
evalu
dilut
particl
individu
ad
human
plasma
quantifi
use
hcv
rna
pcr
kit
correl
expect
concentr
observ
concentr
determin
r
valu
calcul
linear
regress
analysi
fig
result
show
control
could
function
hcv
rna
fluoresc
quantit
assay
calibr
standard
quantif
hcv
rna
influenza
virus
develop
viral
vector
vaccin
develop
gene
therapi
use
plasmidbas
revers
genet
insert
desir
rna
sequenc
influenza
viru
de
baet
et
al
reec
et
al
wu
et
al
similarli
hypothes
chimer
influenza
viru
could
also
use
intern
control
nucleic
acid
test
lipid
envelop
structur
influenza
viru
would
protect
rna
interest
advers
effect
date
chimer
influenza
viru
carri
long
foreign
gene
center
modifi
neuraminidas
na
matrix
protein
ns
gene
influenza
viral
genom
kittel
et
al
li
et
al
manicassami
et
al
wu
et
al
thu
tri
insert
hcv
utr
one
three
gene
chimer
influenza
viru
carri
hcv
utr
success
gener
util
smallest
ns
segment
insert
hcv
utr
ns
segment
analog
viru
previous
report
manicassami
et
al
manicassami
et
al
evalu
inactiv
purifi
chimer
viru
particl
intern
control
routin
clinic
diagnost
rrtpcr
assay
result
show
obtain
chimer
influenza
viru
resist
rnase
stabl
even
plasma
day
moreov
also
show
novel
hcv
posit
control
compar
commerci
armor
rna
control
use
realtim
pcr
detect
hcv
develop
chimer
viral
particl
overcom
limit
nake
rna
control
mainli
instabl
use
influenza
revers
genet
specif
design
rna
packag
virion
therebi
protect
target
rna
rnase
degrad
within
viral
envelop
thu
chimer
virus
use
intern
control
could
stabl
nake
rna
expect
particl
found
resist
rnase
digest
exhibit
improv
storag
handl
properti
ensur
fig
comparison
posit
control
coba
taqman
hcv
test
posit
control
clinic
set
dilut
human
plasma
final
concentr
iuml
store
aliquot
ml
rna
concentr
sampl
assay
per
week
week
coba
taqman
hcv
test
reliabl
qrtpcr
diagnost
assay
although
hcv
rna
within
viral
particl
complet
stabl
temperatur
stabil
preserv
plasma
least
month
could
also
store
month
endur
five
freezethaw
cycl
plasma
addit
chimer
viral
particl
use
control
monitor
entir
process
rrtpcr
assay
includ
rna
extract
step
could
achiev
use
nake
rna
transcript
altern
approach
armor
rna
technolog
strategi
present
could
bypass
patentrel
cost
use
armor
rna
control
lower
cost
method
make
practic
use
routin
clinic
applic
moreov
chimer
viral
particl
could
authent
mimic
target
viru
particl
armor
rna
prepar
similar
genom
organ
surfac
structur
hcv
rna
virus
nevertheless
manipul
intern
gene
face
potenti
problem
must
overcom
theoret
oper
first
influenza
viru
rna
genom
rel
small
limit
length
incorpor
target
rna
garciasastr
pales
foreign
gene
introduc
influenza
viru
usual
restrict
sever
hundr
nucleotid
suitabl
rrtpcr
assay
rna
length
assay
usual
less
base
inde
result
present
indic
hcv
rna
sequenc
could
success
insert
virion
previou
report
shown
gfp
gene
nucleotid
could
packag
propag
use
strategi
indic
possibl
carri
target
gene
nucleotid
manicassami
et
al
investig
requir
determin
techniqu
work
insert
longer
fragment
particularli
import
assay
base
signal
amplif
eg
bdna
hybrid
instead
sequenc
amplif
eg
rrtpcr
second
high
mutat
rate
influenza
rna
genom
may
lead
loss
insert
target
gene
luytj
et
al
howev
chimer
appear
complet
genet
stabl
abl
replic
high
titer
embryon
egg
interestingli
even
eight
passag
embryon
egg
viru
still
show
loss
foreign
hcv
gene
final
infect
may
potenti
disadvantag
routin
use
chimer
influenza
virus
intern
control
falchieri
et
al
influenza
viru
bear
infect
strong
host
specif
mice
noninfecti
human
thu
littl
danger
accident
infect
manufactur
furthermor
embryon
egg
cultur
confirm
chimer
virus
lost
infect
inactiv
formaldehyd
therefor
chimer
viru
particl
develop
intern
control
present
infect
risk
allow
ship
use
safe
nonetheless
proper
clinic
laboratori
safeti
precaut
follow
chimer
viru
particl
repres
genet
modifi
organ
importantli
present
approach
flexibl
insert
differ
foreign
rna
sequenc
influenza
revers
genet
thu
appropri
method
prepar
posit
control
rna
virus
hiv
sarscov
result
control
would
simpl
produc
high
yield
could
standard
accord
standard
oper
procedur
sop
like
use
fig
linear
control
hcv
rna
fluoresc
quantit
assay
particl
dilut
serial
dilut
normal
human
plasma
follow
concentr
iuml
run
perform
triplic
mean
valu
calcul
manufactur
inactiv
influenza
wholeviru
vaccin
moreov
formalin
inactiv
destroy
rna
inhibit
pcr
reaction
avoid
potenti
danger
handl
infecti
control
jong
et
al
conclus
result
demonstr
inactiv
chimer
influenza
viru
particl
use
intern
control
clinic
rrtpcr
assay
close
mimic
true
viral
particl
applic
particl
may
provid
practic
solut
wellknown
problem
come
establish
control
approach
describ
also
appropri
clinic
rrtpcr
assay
rna
virus
clinic
signific
hiv
enteroviru
rna
target
